Omeprazolo Accord Healthcare Uses

What is the dose of your medication?
sponsored

What is Omeprazolo Accord Healthcare?

Omeprazolo Accord Healthcare + SyrSpend SF Alka is a proton pump inhibitor that decreases the amount of acid produced in the stomach.

Omeprazolo Accord Healthcare + SyrSpend SF Alka is used to treat symptoms of gastroesophageal reflux disease (GERD) and other conditions caused by excess stomach acid. Omeprazolo Accord Healthcare + SyrSpend SF Alka is also used to promote healing of erosive esophagitis (damage to your esophagus caused by stomach acid).

Omeprazolo Accord Healthcare + SyrSpend SF Alka may also be given together with antibiotics to treat gastric ulcer caused by infection with Helicobacter pylori (H. pylori).

Over-the-counter (OTC) Omeprazolo Accord Healthcare + SyrSpend SF Alka is used to help control heartburn that occurs 2 or more days per week. Omeprazolo Accord Healthcare + SyrSpend SF Alka + SyrSpend SF Alka not for immediate relief of heartburn symptoms. OTC Omeprazolo Accord Healthcare + SyrSpend SF Alka must be taken on a regular basis for 14 days in a row.

Omeprazolo Accord Healthcare + SyrSpend SF Alka may also be used for purposes not listed in this medication guide.

Omeprazolo Accord Healthcare indications

An indication is a term used for the list of condition or symptom or illness for which the medicine is prescribed or used by the patient. For example, acetaminophen or paracetamol is used for fever by the patient, or the doctor prescribes it for a headache or body pains. Now fever, headache and body pains are the indications of paracetamol. A patient should be aware of the indications of medications used for common conditions because they can be taken over the counter in the pharmacy meaning without prescription by the Physician.
sponsored

Duodenal Ulcer (adults)

Omeprazolo Accord Healthcare is indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.

Omeprazolo Accord Healthcare in combination with clarithromycin and amoxicillin, is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults.

Omeprazolo Accord Healthcare in combination with clarithromycin is indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults.

Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.

Among patients who fail therapy, Omeprazolo Accord Healthcare with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted, and the clarithromycin package insert, Microbiology section.

Gastric Ulcer (Adults)

Omeprazolo Accord Healthcare is indicated for short-term treatment (4-8 weeks) of active benign gastric ulcer in adults.

Treatment Of Gastroesophageal Reflux Disease (GERD) (Adults and Pediatric Patients)

Symptomatic GERD

Omeprazolo Accord Healthcare is indicated for the treatment of heartburn and other symptoms associated with GERD in pediatric patients and adults for up to 4 weeks.

Erosive Esophagitis

Omeprazolo Accord Healthcare is indicated for the short-term treatment (4-8 weeks) of erosive esophagitis that has been diagnosed by endoscopy in pediatric patients and adults.

The efficacy of Omeprazolo Accord Healthcare used for longer than 8 weeks in these patients has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of erosive esophagitis or GERD symptoms (eg, heartburn), additional 4-8 week courses of Omeprazolo Accord Healthcare may be considered.

Maintenance Of Healing Of Erosive Esophagitis (Adults and Pediatric Patients)

Omeprazolo Accord Healthcare is indicated to maintain healing of erosive esophagitis in pediatric patients and adults.

Controlled studies do not extend beyond 12 months.

Pathological Hypersecretory Conditions (Adults)

Omeprazolo Accord Healthcare is indicated for the long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults.

How should I use Omeprazolo Accord Healthcare?

Use Omeprazolo Accord Healthcare delayed-release oral suspension as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Omeprazolo Accord Healthcare delayed-release oral suspension.

Uses of Omeprazolo Accord Healthcare in details

There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.
sponsored

Use: Labeled Indications

Gastroesophageal reflux disease, erosive or nonerosive (Rx only):

Treatment of erosive esophagitis: Short-term treatment of erosive esophagitis (EE) due to acid-mediated gastroesophageal reflux disease (GERD) diagnosed by endoscopy in patients ≥1 year of age; short-term treatment (up to 6 weeks) of EE due to acid-mediated GERD in pediatric patients 1 month to <1 year of age.

Maintenance healing of erosive esophagitis: Maintenance healing of EE due to acid-mediated GERD in patients ≥1 year of age.

Symptomatic gastroesophageal reflux disease: Treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients ≥1 year of age.

Heartburn (OTC only): Treatment of frequent, uncomplicated heartburn (occurring ≥2 or more days per week) in adults.

Helicobacter pylori eradication (Rx only): Treatment of H. pylori infection and duodenal ulcer disease in adults as part of an appropriate combination regimen with antibiotics.

Peptic ulcer disease, treatment of duodenal or gastric ulcers (Rx only): Short-term treatment of active duodenal or gastric ulcers in adults.

Zollinger-Ellison syndrome (Rx only): Long-term treatment of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome, in adults.

Off Label Uses

Aspiration prophylaxis in patients undergoing anesthesia

Data from several studies of varying methodologies (including randomized, double-blind, double-dummy, parallel-group trials) and a meta-analysis support the use of Omeprazolo Accord Healthcare for the prevention of aspiration in patients undergoing anesthesia. Studies were conducted in the elective surgery setting, including scheduled cesarean deliveries.

Based on the Surviving Sepsis Campaign international guidelines for the management of severe sepsis and septic shock, stress ulcer prophylaxis using a PPI is an effective and recommended option in select critically ill patients with GI bleeding risk factors.

Omeprazolo Accord Healthcare description

sponsored

The active ingredient in Omeprazolo Accord Healthcare is a substituted benzimidazole. (RS)-5-methoxy-2(4-methoxy-3,5-dimethyl-2-pyridylmethylsulphinyl) benzimidazole, a compound that inhibits gastric acid secretion. Its empirical formula is C17H19N3O3S, with a molecular weight of 345.42. Omeprazolo Accord Healthcare is a white to off-white crystalline powder which melts with decomposition at about 155°C. It is a weak base, freely soluble in ethanol and methanol, and slightly soluble in acetone and isopropanol and very slightly soluble in water. The stability of Omeprazolo Accord Healthcare is a function of pH; it is rapidly degraded in acid media, but has acceptable stability under alkaline conditions.

Omeprazolo Accord Healthcare is a proton pump inhibitor. It inhibits secretion of gastric acid by irreversibly blocking the enzyme system of hydrogen/potassium adenosine triphosphatase (H+/K+ ATPase), the "proton pump" of the gastric parietal cell. It is used in conditions where inhibition of gastric acid secretion may be beneficial, including aspiration syndromes, dyspepsia, gastro-esophageal reflux disease, peptic ulcer disease and the Zollinger-Ellison syndrome.

Omeprazolo Accord Healthcare dosage

sponsored

Omeprazolo Accord Healthcare Delayed-Release Capsules should be taken before eating. In the clinical trials, antacids were used concomitantly with Omeprazolo Accord Healthcare.

Patients should be informed that the Omeprazolo Accord Healthcare Delayed-Release Capsule should be swallowed whole.

For patients unable to swallow an intact capsule, alternative administration options are available.

Short-Term Treatment Of Active Duodenal Ulcer

The recommended adult oral dose of Omeprazolo Accord Healthcare is 20 mg once daily. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy.

H. pylori Eradication For The Reduction Of The Risk Of Duodenal Ulcer Recurrence

Triple Therapy (Omeprazolo Accord Healthcare/clarithromycin/amoxicillin)

The recommended adult oral regimen is Omeprazolo Accord Healthcare 20 mg plus clarithromycin 500 mg plus amoxicillin 1000 mg each given twice daily for 10 days. In patients with an ulcer present at the time of initiation of therapy, an additional 18 days of Omeprazolo Accord Healthcare 20 mg once daily is recommended for ulcer healing and symptom relief.

Dual Therapy (Omeprazolo Accord Healthcare/clarithromycin)

The recommended adult oral regimen is Omeprazolo Accord Healthcare 40 mg once daily plus clarithromycin 500 mg three times daily for 14 days. In patients with an ulcer present at the time of initiation of therapy, an additional 14 days of Omeprazolo Accord Healthcare 20 mg once daily is recommended for ulcer healing and symptom relief.

Gastric Ulcer

The recommended adult oral dose is 40 mg once daily for 4-8 weeks.

Gastroesophageal Reflux Disease (GERD)

The recommended adult oral dose for the treatment of patients with symptomatic GERD and no esophageal lesions is 20 mg daily for up to 4 weeks. The recommended adult oral dose for the treatment of patients with erosive esophagitis and accompanying symptoms due to GERD is 20 mg daily for 4 to 8 weeks.

Maintenance Of Healing Of Erosive Esophagitis

The recommended adult oral dose is 20 mg daily. Controlled studies do not extend beyond 12 months.

Pathological Hypersecretory Conditions

The dosage of Omeprazolo Accord Healthcare in patients with pathological hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once daily. Doses should be adjusted to individual patient needs and should continue for as long as clinically indicated. Doses up to 120 mg three times daily have been administered. Daily dosages of greater than 80 mg should be administered in divided doses. Some patients with Zollinger-Ellison syndrome have been treated continuously with Omeprazolo Accord Healthcare for more than 5 years.

Pediatric Patients

For the treatment of GERD and maintenance of healing of erosive esophagitis, the recommended daily dose for pediatric patients 1 to 16 years of age is as follows:

Patient Weight Omeprazolo Accord Healthcare Daily Dose
5 < 10 kg 5 mg
10 < 20 kg 10 mg
≥ 20 kg 20 mg

On a per kg basis, the doses of Omeprazolo Accord Healthcare required to heal erosive esophagitis in pediatric patients are greater than those for adults.

Alternative administrative options can be used for pediatric patients unable to swallow an intact capsule.

Alternative Administration Options

Omeprazolo Accord Healthcare is available as a delayed-release capsule or as a delayed-release oral suspension.

For patients who have difficulty swallowing capsules, the contents of a Omeprazolo Accord Healthcare Delayed-Release Capsule can be added to applesauce.

One tablespoon of applesauce should be added to an empty bowl and the capsule should be opened. All of the pellets inside the capsule should be carefully emptied on the applesauce. The pellets should be mixed with the applesauce and then swallowed immediately with a glass of cool water to ensure complete swallowing of the pellets. The applesauce used should not be hot and should be soft enough to be swallowed without chewing. The pellets should not be chewed or crushed. The pellets/applesauce mixture should not be stored for future use.

Omeprazolo Accord Healthcare For Delayed-Release

Oral Suspension should be administered as follows:

For patients with a nasogastric or gastric tube in place:

How supplied

Dosage Forms And Strengths

Omeprazolo Accord Healthcare Delayed-Release Capsules, 10 mg, are opaque, hard gelatin, apricot and amethyst colored capsules, coded 606 on cap and Omeprazolo Accord Healthcare 10 on the body.

Omeprazolo Accord Healthcare Delayed-Release Capsules, 20 mg, are opaque, hard gelatin, amethyst colored capsules, coded 742 on cap and Omeprazolo Accord Healthcare 20 on the body.

Omeprazolo Accord Healthcare Delayed-Release Capsules, 40 mg, are opaque, hard gelatin, apricot and amethyst colored capsules, coded 743 on cap and Omeprazolo Accord Healthcare 40 on the body.

Omeprazolo Accord Healthcare For Delayed-Release

Oral Suspension, 2.5 mg or 10 mg, is supplied as a unit dose packet containing a fine yellow powder, consisting of white to brownish Omeprazolo Accord Healthcare granules and pale yellow inactive granules.

Storage And Handling

Omeprazolo Accord Healthcare Delayed-Release Capsules, 10 mg, are opaque, hard gelatin, apricot and amethyst colored capsules, coded 606 on cap and Omeprazolo Accord Healthcare 10 on the body. They are supplied as follows:

NDC 0186-0606-31 unit of use bottles of 30

Omeprazolo Accord Healthcare Delayed-Release Capsules, 20 mg, are opaque, hard gelatin, amethyst colored capsules, coded 742 on cap and Omeprazolo Accord Healthcare 20 on body. They are supplied as follows:

NDC 0186-0742-31 unit of use bottles of 30

NDC 0186-0742-82 bottles of 1000

Omeprazolo Accord Healthcare Delayed-Release Capsules, 40 mg, are opaque, hard gelatin, apricot and amethyst colored capsules, coded 743 on cap and Omeprazolo Accord Healthcare 40 on the body. They are supplied as follows:

NDC 0186-0743-31 unit of use bottles of 30

NDC 0186-0743-68 bottles of 100

Omeprazolo Accord Healthcare For Delayed-Release

Oral Suspension, 2.5 mg or 10 mg

, is supplied as a unit dose packet containing a fine yellow powder, consisting of white to brownish Omeprazolo Accord Healthcare granules and pale yellow inactive granules. Omeprazolo Accord Healthcare unit dose packets are supplied as follows:

NDC 0186-0625-01 unit dose packages of 30: 2.5 mg packets

NDC 0186-0610-01 unit dose packages of 30: 10 mg packets

Storage

Store Omeprazolo Accord Healthcare Delayed-Release Capsules in a tight container protected from light and moisture. Store between 15°C and 30°C (59°F and 86°F).

Store Omeprazolo Accord Healthcare For Delayed-Release

Oral Suspension at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F).

AstraZeneca Pharmaceuticals LP Wilmington, DE 19850. Revised December 2014

Omeprazolo Accord Healthcare interactions

See also:
What other drugs will affect Omeprazolo Accord Healthcare?

Effects of Omeprazolo Accord Healthcare on the Pharmacokinetics of Other Drugs: The following combination with Omeprazolo Accord Healthcare should be avoided: Ketoconazole and itraconazole.

Omeprazolo Accord Healthcare might influence the absorption of other drugs due to its effect on the gastric pH. The dissolution of ketoconazole tablets in the stomach is adversely affected if the pH of the gastric juice increases as a result of drug treatment (antacids, secretion-inhibiting agents, sucralfate). This leads to ineffective plasma concentrations of ketoconazole. During concomitant administration of Omeprazolo Accord Healthcare and itraconazole, the plasma concentration and area under the curve (AUC) of itraconazole are reduced by approximately 65%, probably as a result of poorer absorption, which is dependent on pH.

Omeprazolo Accord Healthcare inhibits the enzyme CYP2C19 and therefore, increased plasma levels of other drugs (diazepam, warfarin, phenytoin) metabolized via this enzyme might be expected. Monitoring is recommended during initiation or withdrawal of Omeprazolo Accord Healthcare in patients being treated with phenytoin, warfarin or other vitamin K antagonist.

During concomitant administration of clarithromycin or erythromycin and Omeprazolo Accord Healthcare, the plasma concentrations of Omeprazolo Accord Healthcare were increased. The plasma concentrations of Omeprazolo Accord Healthcare are not influenced during concomitant administration with amoxicillin or metronidazole.

Concomitant administration of Omeprazolo Accord Healthcare (40 mg once daily) and atazanavir 300 mg/ritonavir 100 mg to healthy volunteers resulted in a marked reduction in total atazanavir exposure (approximately 75% reduction of AUC, Cmax and Cmin). An increase in the atazanavir dose to 400 mg did not compensate for the effect that Omeprazolo Accord Healthcare had on atazanavir exposure. Proton pump inhibitors including Omeprazolo Accord Healthcare should therefore not be administered concomitantly with atazanavir.

Concomitant administration of Omeprazolo Accord Healthcare and tacrolimus may increase the serum levels of tacrolimus. Monitoring of the plasma tacrolimus concentration is recommended when treatment with Omeprazolo Accord Healthcare is being initiated or discontinued. Omeprazolo Accord Healthcare (40 mg daily) increased the Cmax and AUC of voriconazole (CYP2C19 substrate) by 15% and 41%, respectively.

Effects of Other Drugs on the Pharmacokinetics of Omeprazolo Accord Healthcare: Drugs inhibiting the enzymes CYP2C19 or CYP3A (HIV protease inhibitors, ketoconazole, itraconazole) might increase the plasma concentrations of Omeprazolo Accord Healthcare. Voriconazole increases the AUC of Omeprazolo Accord Healthcare by 280%. In cases of concomitant treatment, an adjustment of the Omeprazolo Accord Healthcare dose should be considered for patients with considerable impaired hepatic function and in cases of long-term treatment.

Case reports, published population pharmacokinetic studies and retrospective analyses suggest that concomitant administration of PPIs and methotrexate (primarily at high doses) may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate. However, no formal drug interaction studies of methotrexate with PPIs have been conducted.

No interactions between Omeprazolo Accord Healthcare and antacids, theophylline, caffeine, quinidine, lidocaine, propranolol, metoprolol or ethanol have been detected.

Omeprazolo Accord Healthcare side effects

See also:
What are the possible side effects of Omeprazolo Accord Healthcare?

Clinical Trials Experience With Omeprazolo Accord Healthcare Monotherapy

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described below reflects exposure to Omeprazolo Accord Healthcare Delayed-Release Capsules in 3096 patients from worldwide clinical trials (465 patients from US studies and 2,631 patients from international studies). Indications clinically studied in US trials included duodenal ulcer, resistant ulcer, and Zollinger-Ellison syndrome. The international clinical trials were double blind and open-label in design. The most common adverse reactions reported (i.e., with an incidence rate ≥ 2%) from Omeprazolo Accord Healthcare-treated patients enrolled in these studies included headache (6.9%), abdominal pain (5.2%), nausea (4.0%), diarrhea (3.7%), vomiting (3.2%), and flatulence (2.7%).

Additional adverse reactions that were reported with an incidence ≥ 1% included acid regurgitation (1.9%), upper respiratory infection (1.9%), constipation (1.5%), dizziness (1.5%), rash (1.5%), asthenia (1.3%), back pain (1.1%), and cough (1.1%).

The clinical trial safety profile in patients greater than 65 years of age was similar to that in patients 65 years of age or less.

The clinical trial safety profile in pediatric patients who received Omeprazolo Accord Healthcare Delayed-Release Capsules was similar to that in adult patients. Unique to the pediatric population, however, adverse reactions of the respiratory system were most frequently reported in both the 1 to < 2 and 2 to 16 year age groups (75.0% and 18.5%, respectively). Similarly, fever was frequently reported in the 1 to 2 year age group (33.0%), and accidental injuries were reported frequently in the 2 to 16 year age group (3.8%).

Clinical Trials Experience With Omeprazolo Accord Healthcare In Combination Therapy For H. pylori Eradication

In clinical trials using either dual therapy with Omeprazolo Accord Healthcare and clarithromycin, or triple therapy with Omeprazolo Accord Healthcare, clarithromycin, and amoxicillin, no adverse reactions unique to these drug combinations were observed. Adverse reactions observed were limited to those previously reported with Omeprazolo Accord Healthcare, clarithromycin, or amoxicillin alone.

Dual Therapy (Omeprazolo Accord Healthcare/clarithromycin)

Adverse reactions observed in controlled clinical trials using combination therapy with Omeprazolo Accord Healthcare and clarithromycin (n = 346) that differed from those previously described for Omeprazolo Accord Healthcare alone were taste perversion (15%), tongue discoloration (2%), rhinitis (2%), pharyngitis (1%) and flu-syndrome (1%). (For more information on clarithromycin, refer to the clarithromycin prescribing information, Adverse Reactions section.)

Triple Therapy (Omeprazolo Accord Healthcare/clarithromycin/amoxicillin)

The most frequent adverse reactions observed in clinical trials using combination therapy with Omeprazolo Accord Healthcare, clarithromycin, and amoxicillin (n = 274) were diarrhea (14%), taste perversion (10%), and headache (7%). None of these occurred at a higher frequency than that reported by patients taking antimicrobial agents alone. (For more information on clarithromycin or amoxicillin, refer to the respective prescribing information, Adverse Reactions sections.)

Post-marketing Experience

The following adverse reactions have been identified during post-approval use of Omeprazolo Accord Healthcare Delayed-Release Capsules. Because these reactions are voluntarily reported from a population of uncertain size, it is not always possible to reliably estimate their actual frequency or establish a causal relationship to drug exposure.

Body As a Whole: Hypersensitivity reactions including anaphylaxis, anaphylactic shock, angioedema, bronchospasm, interstitial nephritis, urticaria,; fever; pain; fatigue; malaise;

Cardiovascular: Chest pain or angina, tachycardia, bradycardia, palpitations, elevated blood pressure, peripheral edema

Endocrine: Gynecomastia

Gastrointestinal: Pancreatitis (some fatal), anorexia, irritable colon, fecal discoloration, esophageal candidiasis, mucosal atrophy of the tongue, stomatitis, abdominal swelling, dry mouth, microscopic colitis. During treatment with Omeprazolo Accord Healthcare, gastric fundic gland polyps have been noted rarely. These polyps are benign and appear to be reversible when treatment is discontinued.

Gastroduodenal carcinoids have been reported in patients with ZE syndrome on long-term treatment with Omeprazolo Accord Healthcare. This finding is believed to be a manifestation of the underlying condition, which is known to be associated with such tumors.

Hepatic: Liver disease including hepatic failure (some fatal), liver necrosis (some fatal), hepatic encephalopathy hepatocellular disease, cholestatic disease, mixed hepatitis, jaundice, and elevations of liver function tests [ALT, AST, GGT, alkaline phosphatase, and bilirubin]

Infections and Infestations: Clostridium difficile associated diarrhea

Metabolism and Nutritional disorders: Hypoglycemia, hypomagnesemia, with or without hypocalcemia and/or hypokalemia, hyponatremia, weight gain

Musculoskeletal: Muscle weakness, myalgia, muscle cramps, joint pain, leg pain, bone fracture

Nervous System/Psychiatric: Psychiatric and sleep disturbances including depression, agitation, aggression, hallucinations, confusion, insomnia, nervousness, apathy, somnolence, anxiety, and dream abnormalities; tremors, paresthesia; vertigo

Respiratory: Epistaxis, pharyngeal pain

Skin: Severe generalized skin reactions including toxic epidermal necrolysis (some fatal), Stevens-Johnson syndrome, and erythema multiforme; photosensitivity; urticaria; rash; skin inflammation; pruritus; petechiae; purpura; alopecia; dry skin; hyperhidrosis

Special Senses: Tinnitus, taste perversion

Ocular: Optic atrophy, anterior ischemic optic neuropathy, optic neuritis, dry eye syndrome, ocular irritation, blurred vision, double vision

Urogenital: Interstitial nephritis, hematuria, proteinuria, elevated serum creatinine, microscopic pyuria, urinary tract infection, glycosuria, urinary frequency, testicular pain

Hematologic: Agranulocytosis (some fatal), hemolytic anemia, pancytopenia, neutropenia, anemia, thrombocytopenia, leukopenia, leucocytosis

Omeprazolo Accord Healthcare contraindications

See also:
What is the most important information I should know about Omeprazolo Accord Healthcare?

You should not take this medication if you are allergic to Omeprazolo Accord Healthcare or to any other benzimidazole medication such as albendazole or mebendazole. Omeprazolo Accord Healthcare is not for immediate relief of heartburn symptoms.

Ask a doctor or pharmacist if it is safe for you to take Omeprazolo Accord Healthcare if you have liver disease or heart disease, or low levels of magnesium in your blood.

Some conditions are treated with a combination of Omeprazolo Accord Healthcare and antibiotics. Use all medications as directed by your doctor. Read the medication guide or patient instructions provided with each medication. Do not change your doses or medication schedule without your doctor's advice.

Take this medication for the full prescribed length of time. Your symptoms may improve before the infection is completely cleared.

Omeprazolo Accord Healthcare OTC (over-the-counter) should be taken for no longer than 14 days in a row. Allow at least 4 months to pass before you start another 14-day treatment.

Heartburn is often confused with the first symptoms of a heart attack. Seek emergency medical attention if you have chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, and a general ill feeling.



Active ingredient matches for Omeprazolo Accord Healthcare:

Omeprazole in Italy.


List of Omeprazolo Accord Healthcare substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
OMEPREN Capsule/ Tablet / 20mg / 10 units (Blue Cross Laboratories Ltd.)$ 0.40
OMEPREN Capsule/ Tablet / 10mg / 10 units (Blue Cross Laboratories Ltd.)$ 0.32
Omepren 20mg HG-CAP / 10 (Blue Cross Laboratories Ltd.)$ 0.52
20 mg x 10's (Blue Cross Laboratories Ltd.)$ 0.52
Omepren 10 mg Capsule (Blue Cross Laboratories Ltd.)$ 0.03
Omepren 20 mg Capsule (Blue Cross Laboratories Ltd.)$ 0.05
OMEPREN 20 MG CAPSULE 1 strip / 10 capsules each (Blue Cross Laboratories Ltd.)$ 0.56
Omepren 20mg Capsule (Blue Cross Laboratories Ltd.)$ 0.06
Omeprol 40 mg x 30's (Sinensix Pharma)
Omeprol gastro-resistant cap 40 mg 30's (Sinensix Pharma)
20 mg x 10's (Prompt Cure Pharma Pvt Ltd)$ 0.57
Omepromp 20 mg Capsule (Prompt Cure Pharma Pvt Ltd)$ 0.06
Omepromp 20mg CAP / 10 (Prompt Cure Pharma Pvt Ltd)$ 0.57
OMEPROMP cap 20 mg x 10's (Prompt Cure Pharma Pvt Ltd)$ 0.57
Omepromp 20mg CAP / 10 (Prompt Cure Pharma Pvt Ltd)$ 0.57
Omepron 40 mg (Westmont)
Omepron 20 mg x 30's (Westmont)$ 26.38
Omepron / vial 40 mg x 1's (Westmont)$ 11.75
Omepron cap 20 mg 30's (Westmont)$ 27.70
Omepron DR cap 40 mg 28's (Westmont)
OMEPROS Capsule/ Tablet / 20mg / 10 units (Sbeed Pharmaceuticals)$ 0.60
Omepros / box, bottle 30's$ 10.79
Omepros 60's$ 19.22
Omepros 100's$ 30.75
OMEPROS D CAPSULE 1 strip / 10 capsules each (Sbeed Pharmaceuticals)$ 0.87

References

  1. DailyMed. "OMEPRAZOLE MAGNESIUM: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "omeprazole". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "omeprazole". http://www.drugbank.ca/drugs/DB00338 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Omeprazolo Accord Healthcare are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Omeprazolo Accord Healthcare. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


Consumer reported time for results

No survey data has been collected yet


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 29 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved